Orchard Therapeutics has just been launched with a €26M investment led by a major investor. It will be developing gene therapies for a range of blood-related disorders in children.
Based in London, Orchard Therapeutics may have just been founded, but it’s based on a long scientific track record. Its founding scientists have been pioneering the area of gene therapy in hematopoietic stem cells (that give origin to all blood cells), in reputable institutions like the Great Ormond Street Hospital (GOSH) and University College London (UCL).
Orchard is having a rather successful start, as its Series A round raised over €26M (£21M). The financing was led by F-Prime Capital, a huge investor in the life sciences, which has already invested in well-known UK biotechs like Adaptimmune, which is developing anti-cancer TCR therapies.
Orchard is developing ex-vivo autologous therapies. This means it can restore the normal gene function of the patient’s own cells in a laboratory. The cells are later transplanted back to differentiate into functioning blood cells.